Hunting the magic bullet in immunotherapy: New forms of old treatment or something completely different?

Clinical and Experimental Allergy

Volumn 31, Issue 7, 2001, Pages 969-974

  Fearby, S ^a   Frew, A J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALLERGEN; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; BEE VENOM; CALCIUM PHOSPHATE; CYTOKINE; EPITOPE; FORMALDEHYDE; FREUND ADJUVANT; GLUTARALDEHYDE; HAPTEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MINERAL OIL; OLIGODEOXYNUCLEOTIDE; PEPTIDE; PHOSPHOLIPASE A; POLYPEPTIDE; POTASSIUM DERIVATIVE; PYRIDINE; UNINDEXED DRUG; UREA;

ANAPHYLAXIS; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ASTHMA; CELL INTERACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DANDER; DERMATOPHAGOIDES PTERONYSSINUS; EDITORIAL; GENE SEQUENCE; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RHINOCONJUNCTIVITIS; RISK FACTOR; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; TARGET CELL; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ANIMALS; HUMANS; IMMUNOTHERAPY;

EID: 0034818879     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01149.x     Document Type: Editorial

References (59)

1. Long term clinical efficacy of grass pollen immunotherapy
2. The discontinuation of Hymenoptera venom immunotherapy. Report from the committee of insects of the American Academy of Allergy Asthma and Immunology
3. Is immunotherapy for asthma worthwhile?
4. Prophylactic innoculation for hay fever
5. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis
6. WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
7. Immunotherapy. Position paper of the European Academy of Allergy and Clinical Immunology
8. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs
9. Effective hyposensitisation in allergic rhinitis using a potent partially purified extract of house dust mite
10. Clinical efficacy of specific immunotherapy to cat dander: A double blind placebo controlled study
11. Immunotherapy as preventative allergy treatment (PAT)
12. Does the effect of immunotherapy last after the termination of treatment? Follow-up study in patients with grass pollen rhinitis
13. Survey of patients after discontinuing venom immunotherapy
14. A placebo-controlled trial with two extracts of D pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in IgE, IgG, and IgG subclasses
15. Evidence for a predominant 'TH2-like' bronchoalveolar lavage T-lymphocyte population in atopic asthma
16. Systemic reactions from allergen immunotherapy
17. A single dose desensitization for summer hay fever
18. Rapid Hymenoptera venom immunotherapy: Comparative safety of three protocols
19. Bee venom immunotherapy induces a shift in cytokine responses from a TH2 to a TH1 dominant pattern: Comparison of rush and conventional immunotherapy
20. Local immunotherapy with Dermatophagoides extract in asthma
21. Safety and efficacy of oral immunotherapy with standardized cat extract
22. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract
23. Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy
24. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants
25. Fine specificity of B-cell epitopes on Felis domesticus allergen I (Fel d I): Effect of reduction, alkylation and deglycosylation on Fel d I structure and antibody binding
26. Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglphus destructor
27. Conversion of the major birch pollen allergen, Bet v 1, into two non-anaphylactic T cell epitope-containing fragments; candidates for a novel form of immunotherapy
28. Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T cell epitopes
29. Randomised control trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
30. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen alergoids by aldehyde modification in two steps
31. Double-blind, placebo controlled immunotherapy with mixed grass aller-goids. Comparison between parameters assessing the efficacy of immunotherapy
32. Effect of Freund's adjuvant on local, draining and circulating lymphocyte populations in sheep
33. IgA and IgG anti-ragweed antibodies in nasal secretions
34. A double blind, placebo controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy
35. A metabolizable adjuvant: Clinical trial of grass pollen-tyrosine adsorbate
36. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (TH1) immunity
37. CpG-oligodeoxynucleotides enhance T cell receptor-triggered interferon gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12
38. Immunostimulatory sequence oligodeoxynucleotide induces an innate type 1 cytokine response from human PBMCs and inhibits IL-4 dependent CD23 expression and IgE production
39. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity
40. Oral administration of CpG oligodeoxynucleotides provides protection against inflammation in asthma
41. Immunologic changes associated with allergen immunotherapy
42. CpG oligodeoxynucleotides do not require Th1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
43. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom allergic subjects
44. Bacterial DNA causes septic shock
45. Oral gene delivery with chitanase-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
46. Follow-up study of the first clinical trial with T cell defined peptides from cat allergen Fel d 1
47. Efficacy of Allervax ragweed peptides in the treatment of ragweed-induced allergy
48. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction
49. CpG DNA as a Th1 trigger
50. Expression and secondary structure determination by NMR methods of the major house dust mite allergen Der p 2
51. Localization of antigenic sites on Der p 2 using oligonucleotide-directed mutagenesis targeted to predicted surface residues
52. Molecular breeding of allergy vaccines and antiallergic cytokines
53. IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist
54. Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs
55. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
56. A potential vaccine strategy for asthma and allied atopic diseases during early childhood
57. Hay fever, hygiene and household size
58. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG
59. Effects of human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response